PCA-Rx is Awaken's living breakthrough solution to toxicity in the body. Without knowing it, people go through life involuntarily collecting a variety of toxins, metals, and other contaminants in their bodies. Everyday circumstances like the air we breathe, the food we eat, disease vaccinations, prescription drugs, and even the place each of us calls home all contribute to the degree of toxic exposure we can experience and eventually suffer from. PCA-Rx / Oral Chelation Resources |
|
Parkinson’s Disease: Can Oral Clathration Help?
PCA-Rx and NG-Rx
Can detoxification with oral clathration agents and other nutritional antioxidants aid persons suffering from Parkinson’s disease? The answer would appear to be that both oral clathration (which is an advancement over chelation therapy) and nutritional intervention with antioxidants can indeed be helpful to such persons.
To be sure, this information is on the cutting edge of complementary medicine. If you have Parkinson’s disease or know someone who does, you or that person should discuss the information in this report with a treating physician. Its importance, however, may be particularly relevant to prevention and for those persons with the early stages of the disease, and, possibly, if the benefits of one’s medications are waning.
Parkinson’s Disease Detoxification Background
Data regarding . . . hepatic detoxification enzyme systems and the body's mechanisms of regulating them suggests the ability to efficiently detoxify and remove xenobiotics can affect these and other chronic disease processes [e.g., Parkinson’s disease], notes by DeAnn J. Liska, Ph.D., in the June 1998 issue of Alternative Medicine Review.
“If research into Parkinson’s disease continues at its present pace, this dreaded disease may well be fully understood and largely preventable early in the 21st Century,” opines Hans R. Larsen, M.Sc. Ch.E. Dr. Larsen asserts that it is now increasingly clear not only what causes Parkinson's, but also how it can be prevented and its relentless progress slowed down.
Neurotoxicity and Parkinson's Disease
Since Parkinson's results from destruction of the dopamine-producing cells, the usual treatment for such patients is to give them L-dopa-containing drugs, along with other medications. This insight has also led researchers to focus on possible destructive influences on the L-dopa producing cells. It is probable that Parkinson’s is a multi-factorial disease with a variety of influences, both genetic and environmental, on its causation. It makes sense, then, to address all potential causes of the disease.
One promising area of research into causes of the disease is its link with environmental neurotoxicity, which may be caused by oxidative stress and heavy metal poisoning.
Many studies have shown that the disease attacks those persons with low levels of natural antioxidants (glutathione and superoxide dismutase) and high levels of iron in the substantia nigra areas of their brains, notes Dr. Larsen. Iron is susceptible to oxidation and may exacerbate free radical reactions that destroy dopamine-producing cells.
DID YOU KNOW? Preventing Parkinson’s — Genetics vs. Environment Prevention (avoiding toxic exposures) and nutritional intervention may be extremely important for reducing the risk of Parkinson's disease, especially since it is not believed to be primarily genetically or age related. The disease probably stems from inherited susceptible genes combined with environmental influences. |
Other metals, especially manganese, cadmium, copper, and mercury (from dental amalgams), have also been implicated as causative factors in the development of Parkinson’s disease. Exposure to aluminum and pesticides (possibly those containing mercury) has been linked to disease onset. Such xenobiotics may also trigger free radical reactions (i.e., oxidative processes) or damage other structural units of the nervous system.
Thus, its onset is not by any means determined at birth. Nevertheless, a family history of the disease is important to take note of, since there may be some genetic susceptibility. Persons with family members who have contracted the disease need to be especially careful to pay attention to prevention early on in life. Even if the disease is not genetic in origin, the same environmental influences that led to its onset in one family member may also cause the disease in other family members. |
Help for Parkinson’s Patients
Nutritional intervention for Parkinson's patients may yield its best results early on in the disease process or as a preventive measure, since cumulative damage may be difficult to reverse. There is only a small amount of data to evaluate when it comes to chelation therapy and Parkinson's disease. Nonetheless, complementary therapy based on an approach utilizing either chelation or oral clathration combined with specific antioxidants, is probably a better healing pathway for such patients than simply adhering to allopathic methods.
We present three such clinical examples that suggest positive results:
- At the Caring Medical & Rehabilitation Clinic, Oak Dale, Illinois, a 73-year-old woman with poor leg circulation and Parkinson's was treated with chelation therapy. This patient had a history of stroke and Parkinson’s since 1996, depression, hypertension, high cholesterol, and blocked arteries in both legs. The patient underwent 24 intravenous chelation treatments and experienced no more tremors since beginning the treatment.
- At the Department of Neurology, Shaare Zedek Medical Center, Jerusalem, Israel, a 47-year-old female dentist suffered from hemiparkinsonism, in which one side of the body is grossly more affected than the other. (Within a few years, the other side becomes affected in virtually all cases.) A baseline urinary mercury excretion analysis indicated very high levels (46 micrograms per day). In this case, the patient was treated with the chelating agent d-penicillamine for one week. Chelation therapy resulted in clinical improvement of Parkinsonism and in dynamic changes in daily urinary mercury excretion with a prompt increase to 79 micrograms/day and a subsequent decline. During a follow-up period of five years, the neurological status remained unchanged after the initial chelation-induced improvement.
- Chelation may also aid patients whose medications’ effectiveness is waning. In a case reported in Clinical Neuropharmacology, a 42-year-old man had suffered from Parkinson's disease for five years. Levodopa was effective, but the wearing-off phenomena were severe. When the chelating agent D-penicillamine was administered, it increased plasma levodopa concentrations, thereby improving his Parkinsonian symptoms. We propose that D-penicillamine facilitates levodopa absorption and, hence, the efficacy of the antiparkinsonian drug.
FYI: Diet & Parkinson’s Disease Diet can also reduce risk of Parkinson’s disease. A high intake of refined sugar can increase its risk. Diets high in vitamin C and carotenoids will reduce risk. Intake of animal fats, which accumulate environmental toxins, is associated with a five-fold increase in the risk of developing the disease. Besides PCA-Rx, consider using vitamin C supplements to delay the need for L-dopa medication. Flavonoids such as grape seed and pine bark extracts, as well as coenzyme Q10, may also be beneficial. |
Case Histories: PCA-Rx Oral Clathration
PCA-Rx is different from chelation agents. It works on the principle of clathration. Its contingent of specifically-sequenced peptides form a lattice or inclusion complex. Multiple receptor sites attach to a toxic molecule with irreversible bonds, literally wrapping around the toxic substance to prevent additional reactions with tissues or organs as it is eliminated from the body.
Case #1. In one case, a mercury-exposed patient began on PCA-Rx for approximately nine days. Post-provocation results showed that with PCA-Rx, mercury excretion increased 2,650 percent from .009 milligrams per kilogram (mg/kg) to .239 mg/kg. Other toxic metals that increased in the stool were arsenic, cadmium, lead, platinum, and thallium.
Case #2. A 58-year-old female was known to be mercury toxic from a dimercaptopropane sulfonate challenge in June 2000. Her amalgam fillings had been removed only two months earlier. Her levels were in the very elevated range. In July, pre-challenge urine and stool samples were collected. The patient then took three doses of PCA-Rx the first day and another urine sample was collected the following morning. The patient was then placed on one dose per day for the following four days. On the fifth day, another urine and stoop sample was taken. PCA-Rx increased lead excretion in the stool by almost fivefold and mercury excretion, also in the stool, by twofold. Urinary excretion increased for lead, arsenic, tin, and thallium.
Prescription for Healthy Living:
Parkinson’s Disease Complementary Treatment Protocol
PCA-Rx. Oral clathration with PCA-Rx from ASN™/Maxam™ Nutraceutics™ appears to be an equally, if not more effective, method of reducing heavy metal burdens without clinical side effects of chelation therapy with medical drugs. Unlike methods of chelation, PCA-Rx does not remove essential minerals or other nutrients while providing often-superior heavy metal removal. Directions: The usual dosage is one to eight sprays under tongue one or more times a day on an empty stomach; hold for one to two minutes. For best results, do not consume anything within 30 minutes of taking.
Antioxidant Environmental Toxin Protection. ASN™/Maxam™ Nutraceutics™ also produces an excellent antioxidant formula known as Antioxidant Environmental Toxin Protection with recommended antioxidants (including pine bark, grape seed, and green tea) for Parkinson’s patients. Directions: Spray into mouth and hold for approximately one to two minutes before swallowing. Use five to ten sprays one or more times each day. No food or drink 30 minutes before or after use.
NG-Rx. NG-Rx is a neurotropic agent thought to aid neural regeneration and should be used in consultation with your treating physician as a complementary therapy. It contains acetyl l-carnitine; phosphatidyl serine; dimethylamino ethanol (DMAE); l-tyrosine and Ginkgo biloba. An experimental study reported in Life Sciences in 1982 showed that supplementation with six to seven grams of tyrosine daily increased the dopamine formation in the brain of patients with Parkinson's disease. However, the nutrient particle sizes in ASN™/Maxam™ Nutraceutics™ products are formulated in nanometers and in a natural colloid that the body recognizes it as a nutrient. These colloidal nanometer particles are better absorbed and, thus, the dosage required for similar benefits may be less.
Availability. Both PCA-Rx and Antioxidant Environmental Toxin Protection are available at natural health centers and from health professionals at ASN/Maxam Nutraceutics. To obtain PCA-Rx or Antioxidant Environmental Toxin Protection, order direct by calling ASN™/Maxam™ Nutraceutics™ toll-free at (800) 800-9119.
